Abstract
Genetic Engineering & Biotechnology NewsVol. 42, No. 5 GENEDGEFirst Patient Dosed with VCTX210, a Cell Therapy for Type 1 DiabetesViaCyte and CRISPR Therapeutics are evaluating an immune-evasive cell replacement therapy that they developed to help patients produce their own insulinAlex PhilippidisAlex PhilippidisSearch for more papers by this authorPublished Online:10 May 2022https://doi.org/10.1089/gen.42.05.02AboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetailsCited byOxidative stress-mediated beta cell death and dysfunction as a target for diabetes management23 September 2022 | Frontiers in Endocrinology, Vol. 13 Volume 42Issue 5May 2022 Information© 2022 by GEN PublishingTo cite this article:Alex Philippidis.First Patient Dosed with VCTX210, a Cell Therapy for Type 1 Diabetes.Genetic Engineering & Biotechnology News.May 2022.10-11.http://doi.org/10.1089/gen.42.05.02Published in Volume: 42 Issue 5: May 10, 2022PDF download
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
